Torna all'elenco degli studi

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9)

CODICE STUDIO

NCT05572515

TIPOLOGIA

Ricaduti

NOME SPONSOR

Janssen Research & Development, LLC

DESCRIZIONE

TRATTAMENTO

Experimental: Teclistamab

Participants will receive Teclistamab monotherapy.

 

Experimental: Pomalidomide, Bortezomib and Dexamethasone (PVd) or Carfilzomib and Dexamethasone (Kd)

Participants will receive either PVd or Kd based on principal investigator’s choice.

Leggi tutto

FARMACI UTILIZZATI

Carfilzomib, Bortezomib (velcade), Teclistamab anticorpo bispecifico, Desametasone